We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHC icon
276
CALL
Bausch Health
BHC
$2.21B
– –
-6,000
Closed -$63.7K
BHVN icon
277
CALL
Biohaven
BHVN
$2.17B
– –
-2,000
Closed -$109K
BHVN icon
278
Biohaven
BHVN
$2.17B
– –
-200
Closed -$10.9K
BYND icon
279
Beyond Meat
BYND
$272M
– –
-577
Closed -$4.78K
CABA icon
280
Cabaletta Bio
CABA
$450M
– –
-8,900
Closed -$152K
CALC icon
281
CalciMedica
CALC
$11.2M
– –
-781
Closed -$3.25K
CMPX icon
282
Compass Therapeutics
CMPX
$358M
– –
-10,206
Closed -$20.2K
DSGN icon
283
Design Therapeutics
DSGN
$862M
– –
-7,200
Closed -$29K
DYN icon
284
Dyne Therapeutics
DYN
$4.83B
– –
-297
Closed -$8.43K
KYNB
285
Kyntra Bio
KYNB
$28.3M
– –
-854
Closed -$50.2K
FORL
286
DELISTED
Four Leaf Acquisition Corp
FORL
– –
-10,000
Closed -$107K
GDX icon
287
VanEck Gold Miners ETF
GDX
$25.6B
– –
-2,000
Closed -$63.2K
GH icon
288
CALL
Guardant Health
GH
$21.1B
– –
-100,000
Closed -$2.06M
GOOGL icon
289
Alphabet (Google) Class A
GOOGL
$4.38T
– –
-2,000
Closed -$302K
GPCR icon
290
CALL
Structure Therapeutics
GPCR
$3.74B
– –
-800
Closed -$34.3K
HOOK
291
DELISTED
HOOKIPA Pharma
HOOK
– –
-5,000
Closed -$35.6K
IGMS
292
DELISTED
IGM Biosciences
IGMS
– –
-4,000
Closed -$38.6K
IMTX icon
293
Immatics
IMTX
$1.29B
– –
-16,200
Closed -$170K
IRON icon
294
Disc Medicine
IRON
$2.97B
– –
-896
Closed -$55.8K
JD icon
295
JD.com
JD
$44.3B
– –
-4,000
Closed -$110K
JSPR icon
296
Jasper Therapeutics
JSPR
$21.5M
– –
-2,406
Closed -$70.6K
KPTI icon
297
Karyopharm Therapeutics
KPTI
$44.2M
– –
-99
Closed -$2.23K
KRYS icon
298
Krystal Biotech
KRYS
$9.55B
– –
-300
Closed -$53.4K
KWEB icon
299
KraneShares CSI China Internet ETF
KWEB
$5.62B
– –
-2,000
Closed -$52.5K
LLY icon
300
Eli Lilly
LLY
$1.06T
– –
-1,865
Closed -$1.45M
10 11
12
13 14

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.